LEADER 04338namaa2200985uu 4500
001 doab100063
003 oapen
005 20230511
006 m o d
007 cr|mn|---annan
008 230511s2023 xx |||||o ||| 0|eng d
020 |a 9783036572161 
020 |a 9783036572178 
020 |a books978-3-0365-7217-8 
024 7 |a 10.3390/books978-3-0365-7217-8  |2 doi 
040 |a oapen  |c oapen 
041 0 |a eng 
042 |a dc 
072 7 |a GP  |2 bicssc 
072 7 |a PH  |2 bicssc 
720 1 |a Choquesillo-Lazarte, Duane  |4 edt 
720 1 |a Choquesillo-Lazarte, Duane  |4 oth 
720 1 |a Dominguez-Martin, Alicia  |4 edt 
720 1 |a Dominguez-Martin, Alicia  |4 oth 
245 0 0 |a Multicomponent Pharmaceutical Solids 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2023 
300 |a 1 online resource (178 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |f Unrestricted online access  |2 star 
520 |a Multicomponent pharmaceutical materials are solids in which at least one component is an active pharmaceutical ingredient (API). This kind of pharmaceutical solid has attracted interest in the past decade as a promising alternative to the laborious and expensive process of traditional pipeline drug development. The application of crystal engineering techniques into the design of pharmaceutical salts, co-crystals, and other multicomponent materials, in addition to the achievement of more environmentally friendly synthetic approaches, has succeeded in modulating the physicochemical, mechanical, and pharmacokinetic properties of drugs, thereby working toward the enhancement of their clinical performance. This Special Issue welcomed original research articles and reviews devoted to all aspects related to the field of multicomponent pharmaceutical solids. Our interests include the fundamentals of applied research, using theoretical and experimental approaches, the development of synthetic methods, the screening of multicomponent materials, structure-activity rationale, the salt-co-crystal continuum identification, the enhancement in physicochemical/mechanical/pharmacokinetic performance, as well as the functionality and applications of multicomponent pharmaceuticals solids. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |u https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Physics  |2 bicssc 
650 7 |a Research & information: general  |2 bicssc 
653 |a aminoglutethimide 
653 |a amorphous drug 
653 |a API 
653 |a aripiprazole 
653 |a bilastine 
653 |a characterization methods 
653 |a cocrystals 
653 |a controlled release 
653 |a crystal engineering 
653 |a crystal structure 
653 |a crystal structure determination 
653 |a crystallization 
653 |a DFT 
653 |a DFT calculations 
653 |a diclofenac 
653 |a dissolution 
653 |a drug-drug cocrystal 
653 |a ethenzamide 
653 |a eutectic mixture 
653 |a furosemide 
653 |a H-bonding 
653 |a lidocaine 
653 |a mandelic acid 
653 |a mechanochemical synthesis 
653 |a mechanochemistry 
653 |a melt phase diagram 
653 |a molecular mobility 
653 |a multicomponent crystal 
653 |a multicomponent materials 
653 |a multicomponent solids 
653 |a n/a 
653 |a nucleobases 
653 |a pharmaceutical solid forms 
653 |a pharmaceutical solids 
653 |a physical stability 
653 |a piroxicam 
653 |a polymorph 
653 |a pyridinecarboxamides 
653 |a single crystal X-ray diffraction 
653 |a solubility 
653 |a solvate 
653 |a squaric acid 
653 |a structure determination from powder diffraction 
653 |a theophylline 
653 |a X-ray structure 
653 |a xanthines 
793 0 |a DOAB Library. 
856 4 0 |u https://directory.doabooks.org/handle/20.500.12854/100063  |7 0  |z Open Access: DOAB: description of the publication 
856 4 0 |u https://mdpi.com/books/pdfview/book/7156  |7 0  |z Open Access: DOAB, download the publication